Variants of the CYP11B2 gene predict response to therapy with candesartan.
Eur J Pharmacol
; 445(1-2): 151-2, 2002 Jun 07.
Article
em En
| MEDLINE
| ID: mdl-12065207
ABSTRACT
In a prospective trial, patients with an elevated diastolic blood pressure (above 95 mm Hg) received high-dose (16 mg) or low-dose (8 mg) candesartan in addition to standardised medication. A positive response to treatment was defined as a diastolic blood pressure <85 mm Hg at follow-up. Genotyping for two candidate genes was performed in 116 patients. Genotypes of the CYP11B2 promotor polymorphism significantly predicted a positive response to treatment (CC 67%; TC 34%; TT 21%; p=0.005).
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tetrazóis
/
Benzimidazóis
/
Citocromo P-450 CYP11B2
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur J Pharmacol
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Alemanha